Benefit of angiographic spontaneous reperfusion in STEMI: Does it extend to diabetic patients?

Heart

Volumn 95, Issue 16, 2009, Pages 1331-1336

  Bainey, K R ^a   Fu, Y ^a   Granger, C B ^b   Hamm, C W ^c   Holmes Jr , D R ^d   O'Neill, W W ^e   Seabra Gomes, R ^f   Pfisterer, M E ^g   Van De Werf, F ^h   Armstrong, P W ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^c KERCKHOFF HEART CENTER   (Germany)

^d MAYO CLINIC   (United States)

^e UNIVERSITY OF MIAMI   (United States)

^f Instituto do Coracao   (Portugal)

^g UNIVERSITY HOSPITAL BASEL   (Switzerland)

^h UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; FIBRINOGEN RECEPTOR ANTAGONIST; GLUCOSE; PEXELIZUMAB; PLACEBO;

ADULT; ADVERSE OUTCOME; ANGIOCARDIOGRAPHY; ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DIABETIC PATIENT; FEMALE; GLUCOSE BLOOD LEVEL; HEART INFARCTION; HEART MUSCLE BLOOD FLOW; HEART MUSCLE REPERFUSION; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SHOCK; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; TREATMENT RESPONSE;

AGED; ANTIBODIES, MONOCLONAL; CORONARY ANGIOGRAPHY; DIABETIC ANGIOPATHIES; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION; REMISSION, SPONTANEOUS; SINGLE-CHAIN ANTIBODIES; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 68049133157     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/hrt.2008.160390     Document Type: Article

References (28)

1. Mak KH, Moliterno DJ, Granger CB, et al. Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction. GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. J Am Coll Cardiol 1997;30:171-9.
2. Haffner SM, Lehto S, Ronnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229-34.
3. Stone GW, Cox D, Garcia E, et al. Normal flow (TIMI-3) before mechanical reperfusion therapy is an independent determinant of survival in acute myocardial infarction: analysis from the primary angioplasty in myocardial infarction trials. Circulation 2001;104:636-41.
4. Kwaan HC. Changes in blood coagulation, platelet function, and plasminogen-plasmin system in diabetes. Diabetes 1992;41(Suppl 2):32-5.
5. McGill JB, Schneider DJ, Arfken CL, et al. Factors responsible for impaired fibrinolysis in obese subjects and NIDDM patients. Diabetes 1994;43:104-9.
6. Armstrong PW, Granger CB, Adams PX, et al. Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: a randomized controlled trial. JAMA 2007;297:43-51.
7. Armstrong PW, Adams PX, Al-Khalidi HR, et al. Assessment of Pexelizumab in Acute Myocardial Infarction (APEX AMI): a multicenter, randomized, double-blind, parallel-group, placebo-controlled study of pexelizumab in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. Am Heart J 2005;149:402-7.
8. Schroder R, Wegscheider K, Schroder K, et al. Extent of early ST segment elevation resolution: a strong predictor of outcome in patients with acute myocardial infarction and a sensitive measure to compare thrombolytic regimens. A substudy of the International Joint Efficacy Comparison of Thrombolytics (INJECT) trial. J Am Coll Cardiol 1995;26:1657- 64.
9. Pinto DS, Kirtane AJ, Pride YB, et al. Association of blood glucose with angiographic and clinical outcomes among patients with ST-segment elevation myocardial infarction (from the CLARITY-TIMI-28 study). Am J Cardiol 2008;101:303-7.
10. Winocour PD. Platelet abnormalities in diabetes mellitus. Diabetes 1992;41(Suppl 2):26-31.
11. Davi G, Catalano I, Averna M, et al. Thromboxane biosynthesis and platelet function in type II diabetes mellitus. N Engl J Med 1990;322:1769-74.
12. Calverley DC, Hacker MR, Loda KA, et al. Increased platelet Fc receptor expression as a potential contributing cause of platelet hypersensitivity to collagen in diabetes mellitus. Br J Haematol 2003;121:139-42.
13. Gray RP, Patterson DL, Yudkin JS. Plasminogen activator inhibitor activity in diabetic and nondiabetic survivors of myocardial infarction. Arterioscler Thromb 1993;13:415-20.
14. Nordt TK, Bode C. Impaired endogenous fibrinolysis in diabetes mellitus: mechanisms and therapeutic approaches. Semin Thromb Hemost 2000;26:495-501.
15. Quinones MJ, Hernandez-Pampaloni M, Schelbert H, et al. Coronary vasomotor abnormalities in insulin-resistant individuals. Ann Intern Med 2004;140:700-8.
16. Hsueh WA, Lyon CJ, Quinones MJ. Insulin resistance and the endothelium. Am J Med 2004;117:109-17.
17. Angeja BG, de Lemos J, Murphy SA, et al. Impact of diabetes mellitus on epicardial and microvascular flow after fibrinolytic therapy. Am Heart J 2002;144:649-56.
18. Prasad A, Stone GW, Stuckey TD, et al. Impact of diabetes mellitus on myocardial perfusion after primary angioplasty in patients with acute myocardial infarction. J Am Coll Cardiol 2005;45:508-14.
19. Marso SP, Miller T, Rutherford BD, et al. Comparison of myocardial reperfusion in patients undergoing percutaneous coronary intervention in ST-segment elevation acute myocardial infarction with versus without diabetes mellitus (from the EMERALD Trial). Am J Cardiol 2007;100:206-10.
20. Biondi-Zoccai GG, Abbate A, Liuzzo G, et al. Atherothrombosis, inflammation, and diabetes. J Am Coll Cardiol 2003;41:1071-7.
21. Creager MA, Luscher TF, Cosentino F, et al. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: Part I. Circulation 2003;108:1527-32.
22. Capes SE, Hunt D, Malmberg K, et al. Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview. Lancet 2000;355:773-8.
23. Kadri Z, Danchin N, Vaur L, et al. Major impact of admission glycaemia on 30 day and one year mortality in non-diabetic patients admitted for myocardial infarction: results from the nationwide French USIC 2000 study. Heart 2006;92:910-5.
24. Iwakura K, Ito H, Ikushima M, et al. Association between hyperglycemia and the no-reflow phenomenon in patients with acute myocardial infarction. J Am Coll Cardiol 2003;41:1-7.
25. Worthley MI, Shrive FM, Anderson TJ, et al. Prognostic implication of hyperglycemia in myocardial infarction and primary angioplasty. Am J Med 2007;120:643.e1-7.
26. Timmer JR, Ottervanger JP, de Boer MJ, et al. Hyperglycemia is an important predictor of impaired coronary flow before reperfusion therapy in ST-segment elevation myocardial infarction. J Am Coll Cardiol 2005;45:999-1002.
27. Shechter M, Merz CN, Paul-Labrador MJ, et al. Blood glucose and platelet-dependent thrombosis in patients with coronary artery disease. J Am Coll Cardiol 2000;35:300-7.
28. Vehkavaara S, Seppala-Lindroos A, Westerbacka J, et al. In vivo endothelial dysfunction characterizes patients with impaired fasting glucose. Diabetes Care 1999;22:2055-60.